Autolus Therapeutics plc (AUTL)
↓ Download CSV- Sector Manufacturing
- Incorporated X0
- Fiscal year ends Dec 31
In fiscal 2025, Autolus Therapeutics plc reported revenue of $75.39M, up 644.9% from the prior year. The company ran a net loss, with a net margin of -381.4%. It held $589.07M in total assets against $410.94M in total liabilities.
Key ratios (FY2025)
-358.9%
Operating margin
-381.4%
Net margin
-161.4%
Return on equity
+644.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.39M | $10.12M | — | — | — | — | — | — | — | — |
| Cost of Revenue | $96.37M | $11.39M | $0 | — | — | — | — | — | — | — |
| Operating Income | -$270.54M | -$241.43M | -$179.70M | -$143.41M | -$141.05M | -$168.15M | -$146.06M | -$57.53M | -$23.42M | — |
| Net Income | -$287.53M | -$220.66M | -$208.38M | -$148.84M | -$142.10M | -$142.09M | -$123.85M | -$44.75M | -$19.73M | -$12.55M |
| EPS (Diluted) | $-1.08 | $-0.86 | $-1.20 | $-1.57 | $-1.97 | $-2.76 | $-2.88 | — | — | — |
| Total Assets | $589.07M | $782.73M | $375.38M | $490.27M | $405.56M | $294.24M | $303.53M | $254.21M | $148.66M | — |
| Total Liabilities | $410.94M | $355.40M | $263.91M | $191.60M | $92.24M | $84.20M | $48.69M | $21.57M | $6.06M | — |
| Shareholders' Equity | $178.13M | $427.32M | $111.47M | $298.67M | $313.32M | $210.03M | $254.84M | $232.64M | $142.60M | $30.69M |
| Cash & Equivalents | $104.13M | $227.38M | $239.57M | $382.44M | $310.34M | — | — | — | — | — |
| Operating Cash Flow | -$283.57M | -$206.27M | -$145.59M | -$112.31M | -$117.86M | -$117.76M | -$101.48M | -$31.54M | -$16.36M | -$9.85M |
| Capital Expenditures | $19.04M | $22.07M | $10.99M | $10.84M | $8.86M | $14.68M | $18.34M | $9.12M | $2.88M | $1.85M |
| Shares Outstanding | 266.14M | 255.16M | 173.94M | 94.99M | 72.08M | 51.56M | 43.07M | — | — | — |